Mirion Technologies , Inc. (NYSE:MIR) Chief Financial Officer Brian Schopfer recently sold 75,000 shares of Class A common stock, generating proceeds of approximately $1.37 million. The shares were sold at an average price of $18.27 each, near the company’s 52-week high of $18.90. Following this transaction, Schopfer holds 919,432 shares directly in the $3.79 billion market cap company. According to InvestingPro analysis, the stock has delivered an impressive 66% return over the past year.
In addition to the sale, Schopfer acquired 75,000 shares of Class A common stock through the redemption of an equivalent number of Class B shares. This transaction was part of a previously adopted trading plan under Rule 10b5-1, which is designed to allow company insiders to sell a predetermined number of shares at a set time.
These transactions reflect ongoing stock management activities by Schopfer, who continues to hold a significant position in Mirion Technologies.
In other recent news, Mirion Technologies reported its first-quarter 2025 financial results, which exceeded Wall Street expectations. The company posted an adjusted earnings per share (EPS) of $0.10, surpassing the projected $0.08, and achieved revenue of $202 million, slightly above the anticipated $199.34 million. This strong performance was driven by a 6% year-over-year revenue growth, with notable gains in the Nuclear Safety and Nuclear Power segments. Additionally, Mirion Technologies announced plans to offer $300 million in Convertible Senior Notes due 2030, with proceeds intended for strategic actions such as repurchasing Class A common stock and repaying senior secured term loans.
The company maintained its full-year 2025 guidance and highlighted a project pipeline valued between $300 million and $400 million, with expectations for most projects to materialize in the latter half of the year. Mirion Technologies also announced the acquisition of a small software business, OncoSpace, to enhance its cancer care portfolio. Analyst feedback from firms like Goldman Sachs and Citigroup (NYSE:C) indicates cautious optimism about the company’s strategic initiatives and market position. These developments reflect Mirion’s ongoing efforts to strengthen its financial standing and operational capabilities in the evolving nuclear and medical sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.